{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:33:25Z","timestamp":1761215605248,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background\/Objectives: Cystic fibrosis (CF) is a multisystemic and genetic disorder. Mutations in the CF transmembrane conductance regulator (CFTR) gene impair the function of the CFTR protein, leading to various complications in multiple organs, mainly the lungs. Methods: In this article, we have tried to investigate the potential impact of CFTR modulators on bone density, muscle mass, and strength in children and young adolescents with CF by using the existing literature and conducting a narrative (non-systematic) review. Results: It has been demonstrated that CFTR modulators may positively influence bone mineral density. On the other hand, the impact of CFTR modulators on muscle mass and strength seems to vary among studies. Conclusions: Besides the current literature, further studies are needed to validate the existing claims.<\/jats:p>","DOI":"10.3390\/children12111434","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:44:30Z","timestamp":1761212670000},"page":"1434","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cystic Fibrosis and CFTR Modulators: The Impact on Bone Density, Muscle Mass and Strength in Children and Young Adolescents"],"prefix":"10.3390","volume":"12","author":[{"given":"Katerina","family":"Iordanidou","sequence":"first","affiliation":[{"name":"Department of Nutrition and Dietetics, School of Physical Education, Sport Science and Dietetics, University of Thessaly, 42100 Trikala, Greece"},{"name":"Pediatric Pulmonology and Cystic Fibrosis Unit, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-7042","authenticated-orcid":false,"given":"Nikolaos D.","family":"Karakousis","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Dietetics, School of Physical Education, Sport Science and Dietetics, University of Thessaly, 42100 Trikala, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-2054","authenticated-orcid":false,"given":"Elpis","family":"Hatziagorou","sequence":"additional","affiliation":[{"name":"Pediatric Pulmonology and Cystic Fibrosis Unit, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisavet-Anna","family":"Chrysochoou","sequence":"additional","affiliation":[{"name":"Pediatric Pulmonology and Cystic Fibrosis Unit, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0555-3198","authenticated-orcid":false,"given":"Maria","family":"Galogavrou","sequence":"additional","affiliation":[{"name":"Pediatric Pulmonology and Cystic Fibrosis Unit, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Sopiadou","sequence":"additional","affiliation":[{"name":"Pediatric Pulmonology and Cystic Fibrosis Unit, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Papagianni","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Dietetics, School of Physical Education, Sport Science and Dietetics, University of Thessaly, 42100 Trikala, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1891\/NN-2022-0007","article-title":"Cystic Fibrosis: Back to the Basics","volume":"42","author":"Myer","year":"2023","journal-title":"Neonatal Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: Current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Baroni, D. (2025). Unraveling the Mechanism of Action, Binding Sites, and Therapeutic Advances of CFTR Modulators: A Narrative Review. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47020119"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: A disease with a new face","volume":"109","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_5","first-page":"CD011231","article-title":"Airway clearance techniques for cystic fibrosis: An overview of Cochrane systematic reviews","volume":"1","author":"Wilson","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s10495-014-1014-z","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) prevents apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells","volume":"19","author":"Zeng","year":"2014","journal-title":"Apoptosis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e13708","DOI":"10.1002\/jcsm.13708","article-title":"Defective Cystic Fibrosis Transmembrane Conductance Regulator Accelerates Skeletal Muscle Aging by Impairing Autophagy\/Myogenesis","volume":"16","author":"Chen","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s41030-025-00303-4","article-title":"Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis","volume":"11","author":"Rubin","year":"2025","journal-title":"Pulm. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccm.2022.06.013","article-title":"Endocrine Complications of Cystic Fibrosis","volume":"43","author":"Kelly","year":"2022","journal-title":"Clin. Chest Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":"The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: A systematic literature review with meta-analysis","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1440-1754.2008.01406.x","article-title":"Bone mass density and associated factors in cystic fibrosis patients of young age","volume":"44","author":"Douros","year":"2008","journal-title":"J. Paediatr. Child Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1164\/rccm.200606-776OC","article-title":"Low bone mineral density in young children with cystic fibrosis","volume":"175","author":"Souberbielle","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","first-page":"807","article-title":"A retrospective analysis of longitudinal changes in bone mineral content in cystic fibrosis","volume":"30","author":"Shepherd","year":"2017","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-3476(96)70424-9","article-title":"Bone density in children and adolescents with cystic fibrosis","volume":"128","author":"Henderson","year":"1996","journal-title":"J. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nut.2018.03.052","article-title":"Cystic fibrosis, body composition, and health outcomes: A systematic review","volume":"55\u201356","author":"Calella","year":"2018","journal-title":"Nutrition"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jcf.2019.08.018","article-title":"Cystic fibrosis bone disease: Pathophysiology, assessment and prognostic implications","volume":"18","author":"Anabtawi","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jcf.2015.04.005","article-title":"Cystic fibrosis-related bone disease in children: Examination of peripheral quantitative computed tomography (pQCT) data","volume":"14","author":"Brookes","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: Current knowledge and future directions","volume":"18","author":"Putman","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcf.2009.11.005","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone","volume":"9","author":"Guillaume","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.ajpath.2012.01.039","article-title":"The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation","volume":"180","author":"Gimenez","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1113\/jphysiol.2010.202861","article-title":"The most common cystic fibrosis-associated mutation destabilizes the dimeric state of the nucleotide-binding domains of CFTR","volume":"589","author":"Jih","year":"2011","journal-title":"J. Physiol."},{"key":"ref_24","first-page":"e16144","article-title":"A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.chest.2018.04.036","article-title":"Ion Channel Modulators in Cystic Fibrosis","volume":"154","author":"Gentzsch","year":"2018","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kapouni, N., Moustaki, M., Douros, K., and Loukou, I. (2023). Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. Children, 10.","DOI":"10.3390\/children10030554"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrd3723","article-title":"Ivacaftor","volume":"11","author":"Davis","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40265-016-0611-2","article-title":"Lumacaftor\/Ivacaftor: A Review in Cystic Fibrosis","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1248","DOI":"10.1210\/clinem\/dgaa890","article-title":"The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis","volume":"106","author":"Putman","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Boni, A., d\u2019Aniello, F., Ubertini, G., Cappa, M., Ciciriello, F., Majo, F., Cristiani, L., Alghisi, F., Montemitro, E., and Bella, S. (2025). Height Velocity in Pediatric Cystic Fibrosis Under Triple CFTR Modulator Therapy: A Real-Life Monocentric Experience. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155259"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e71044","DOI":"10.1002\/ppul.71044","article-title":"Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor: A Cross-Sectional Single-Centre Study","volume":"60","author":"Clayton","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e27463","DOI":"10.1002\/ppul.27463","article-title":"Growth, Body Composition, and Strength of Children with Cystic Fibrosis Treated with Elexacaftor\/Tezacaftor\/Ivacaftor (ETI)","volume":"60","author":"Boat","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Imrei, M., Keri, A.F., Gacs, E., Gonczi, I., Melath, M., Kosaras, E., Demeter, B., Peterfia, C., Vass, K., and Szekely, G. (2025). Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-86010-1"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e26729","DOI":"10.1016\/j.heliyon.2024.e26729","article-title":"One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis","volume":"10","author":"Penelle","year":"2024","journal-title":"Heliyon"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcf.2022.05.009","article-title":"Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor\/Ivacaftor and Tezacaftor\/Ivacaftor","volume":"21","author":"Rysgaard","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Garcia-Perez-de-Sevilla, G., Blanco Velasco, A., Yvert, T., Sanz-Santiago, V., Tirado, A.M., Lopez Neyra, A., de Manuel, C., Ruiz Valbuena, M., and Perez-Ruiz, M. (2025). Respiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies. Children, 12.","DOI":"10.3390\/children12070878"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","article-title":"The National Osteoporosis Foundation\u2019s position statement on peak bone mass development and lifestyle factors: A systematic review and implementation recommendations","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_42","first-page":"172","article-title":"Bone metabolism in children and adolescents: Main characteristics of the determinants of peak bone mass","volume":"10","author":"Stagi","year":"2013","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dumortier, C., Danopoulos, S., Velard, F., and Al Alam, D. (2021). Bone Cells Differentiation: How CFTR Mutations May Rule the Game of Stem Cells Commitment?. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.611921"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin. Nutr."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/11\/1434\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:10:55Z","timestamp":1761214255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/11\/1434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["children12111434"],"URL":"https:\/\/doi.org\/10.3390\/children12111434","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}